Seasonal flu vaccines work, but modestly: their effectiveness swings with how well manufacturers guessed the coming season’s strains months in advance, using a production process built on eggs and patience. mRNA technology promises a faster, closer match, and trials are testing whether the promise survives contact with a virus that has outwitted vaccinologists for decades.
Why flu is a hard target
Influenza mutates relentlessly and circulates as a family of strains whose proportions shift between hemispheres and seasons. Vaccine composition is chosen many months ahead to allow manufacturing, and in mismatch years protection drops, sometimes badly, through no failure of the vaccine that was made, only of the forecast it was made from.
The egg-based production system adds its own distortion: the virus adapts to growing in eggs, occasionally changing the very features the vaccine must teach the immune system to recognise. Alternative production in cell cultures reduced that problem without eliminating the forecasting one.
What mRNA changes
Speed is the headline advantage. Once a strain is chosen, an mRNA vaccine’s sequence can be finalised in days and manufactured without growing virus at all, compressing the calendar and allowing later, better-informed strain choices. Updating for a drifted strain mid-programme becomes conceivable in a way it never was with eggs.
The platform also invites combination products: flu strains, COVID and RSV in a single injection, an attractive proposition for clinics and patients alike. Several such combinations are in trials, with convenience as their clearest selling point.
What the trials must prove
Enthusiasm meets a stubborn benchmark: the existing vaccines are safe, cheap and familiar, and a replacement must beat them on effectiveness, tolerability or both. Early mRNA flu results showed strong responses against some strains and weaker ones against others, particularly the B lineages, and side effects, sore arms, brief fevers, ran higher than with conventional shots.
Researchers are iterating on the design: dose, sequence engineering and delivery, aiming to keep the immunological gains while calming the reactogenicity. The platform’s adjustability is its advantage in this process; each flu season’s trial can incorporate the last one’s lessons.
For more coverage of the stories shaping the day, visit our homepage and the latest reporting in Blogs.
Cost and access questions
mRNA manufacturing is scaling and cheapening, but seasonal flu is one of the lowest-priced vaccine markets in existence, bought in hundreds of millions of doses. A premium product must justify itself to procurement agencies with effectiveness data, not novelty, and the early years will likely see it used selectively rather than universally.
Manufacturing geography matters too. The pandemic built mRNA capacity on several continents, and seasonal flu production could anchor that capacity between emergencies, keeping facilities and expertise warm for the next crisis, an argument governments find persuasive beyond the flu numbers themselves.
The universal vaccine horizon
Behind the seasonal upgrade sits the field’s real prize: a vaccine targeting the parts of the virus that do not change, offering durable protection across strains and years. mRNA is one of several platforms being used to test conserved-target designs that were impractical to manufacture before.
Nobody promises that prize on a schedule. But the path now visible, incremental platform improvements in the seasonal product funding and informing the universal research, is how vaccinology has always advanced: boring iteration in public, breakthrough in retrospect.
Further reading: Nature and National Institutes of Health.
Flu kills hundreds of thousands in a bad year, quietly enough to be underestimated. A better vaccine would not make headlines for a single dramatic rescue; it would simply subtract suffering at scale, season after season, which is what the best public health always does.
